Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EBITDA (2016 - 2025)

Bioadaptives' EBITDA history spans 7 years, with the latest figure at -$248117.0 for Q4 2025.

  • On a quarterly basis, EBITDA rose 26.45% to -$248117.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.0 million, a 73.09% decrease, with the full-year FY2025 number at -$1.0 million, down 73.09% from a year prior.
  • EBITDA hit -$248117.0 in Q4 2025 for Bioadaptives, up from -$265689.0 in the prior quarter.
  • Over the last five years, EBITDA for BDPT hit a ceiling of -$18975.0 in Q1 2023 and a floor of -$337339.0 in Q4 2024.
  • Historically, EBITDA has averaged -$146558.2 across 5 years, with a median of -$132619.0 in 2022.
  • Biggest five-year swings in EBITDA: crashed 897.05% in 2021 and later surged 89.11% in 2023.
  • Tracing BDPT's EBITDA over 5 years: stood at -$177734.0 in 2021, then surged by 84.64% to -$27302.0 in 2022, then crashed by 126.3% to -$61784.0 in 2023, then crashed by 446.0% to -$337339.0 in 2024, then increased by 26.45% to -$248117.0 in 2025.
  • Business Quant data shows EBITDA for BDPT at -$248117.0 in Q4 2025, -$265689.0 in Q3 2025, and -$279219.0 in Q2 2025.